Literature DB >> 30306528

Melatonin: A New-Generation Therapy for Reducing Chronic Pain and Improving Sleep Disorder-Related Pain.

Tavleen Kaur1, Bai-Chuang Shyu2,3.   

Abstract

Melatonin is an endogenous neurohormone that is produced in most living organisms, including unicellular and multicellular organisms, plants, vertebrates, and nonvertebrate animals. In diurnal animals, endogenous melatonin functions as a neurohormone and contributes to circadian rhythms. In nocturnal animals, endogenous melatonin no longer functions as a contributor to circadian rhythms. Circadian rhythms control the timing, quantity, and quality of hormones and neurotransmitters that the body produces and eventually secretes. An imbalance of these events creates disturbances in circadian rhythm. During disturbances of circadian rhythm, the body produces hormones, chemicals, and neurotransmitters in aberrant amounts or at the wrong time of day. The human circadian system is synchronized with physiological functions and metabolism. Many studies have reported that exogenous melatonin has analgesic and neuroprotective effects in chronic pain. Considering that chronotherapy may be beneficial for the treatment of chronic pain, the present review describes the properties, possible mechanisms, and function of melatonin in chronic pain.

Entities:  

Keywords:  Central poststroke pain; Chronic pain; Chronotherapy; Circadian rhythms; Melatonin; Neuroprotection

Mesh:

Substances:

Year:  2018        PMID: 30306528     DOI: 10.1007/978-981-13-1756-9_19

Source DB:  PubMed          Journal:  Adv Exp Med Biol        ISSN: 0065-2598            Impact factor:   2.622


  4 in total

Review 1.  Sleep and pain: recent insights, mechanisms, and future directions in the investigation of this relationship.

Authors:  Alberto Herrero Babiloni; Beatrice P De Koninck; Gabrielle Beetz; Louis De Beaumont; Marc O Martel; Gilles J Lavigne
Journal:  J Neural Transm (Vienna)       Date:  2019-08-26       Impact factor: 3.575

Review 2.  At the intersection of sleep deficiency and opioid use: mechanisms and therapeutic opportunities.

Authors:  Mark K Greenwald; Tabitha E H Moses; Timothy A Roehrs
Journal:  Transl Res       Date:  2021-03-09       Impact factor: 10.171

3.  Phase II double-blind randomised controlled trial of exogenous administration of melatonin in chronic pain (DREAM-CP): a study protocol.

Authors:  Rosalind Adam; Saravanakumar Kanakarajan; Uzunma Onyeakazi; Malachy Columb; Helen Galley
Journal:  BMJ Open       Date:  2020-03-16       Impact factor: 2.692

4.  Associations of frequent pain symptoms with excessive daytime sleepiness in adolescents: a longitudinal study.

Authors:  Xianchen Liu; Zhen-Zhen Liu; Yanyun Yang; Cun-Xian Jia
Journal:  J Clin Sleep Med       Date:  2021-12-01       Impact factor: 4.062

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.